Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN)

Market Closed
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
567. 74
+7.98
+1.43%
$
58.1B Market Cap
24.52 P/E Ratio
0% Div Yield
844,600 Volume
42.79 Eps
$ 559.76
Previous Close
Day Range
551.48 568.46
Year Range
476.49 1,211.2
Want to track REGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 17 days
Regeneron shares plunge after mixed COPD drug trial results

Regeneron shares plunge after mixed COPD drug trial results

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company's experimental COPD drug, developed with partner Sanofi SA (ADR) (NYSE:SNY), posted mixed results in two Phase 3 trials—casting doubt on its regulatory path and delaying hopes for a major new revenue stream. The drug, itepekimab, reduced moderate or severe flare-ups by 27% compared to placebo over 52 weeks in the AERIFY-1 study, which enrolled 1,127 former smokers with chronic obstructive pulmonary disease (COPD).

Proactiveinvestors | 1 month ago
Regeneron Initial Data on Multiple Myeloma Drug Encouraging

Regeneron Initial Data on Multiple Myeloma Drug Encouraging

REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.

Zacks | 1 month ago
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine.

Seekingalpha | 1 month ago
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

Zacks | 1 month ago
Regeneron Buys 23andMe in Bankruptcy Auction

Regeneron Buys 23andMe in Bankruptcy Auction

Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.

Investopedia | 1 month ago
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.

Nypost | 1 month ago
Regeneron to buy 23andMe out of bankruptcy for $256m

Regeneron to buy 23andMe out of bankruptcy for $256m

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech firm filed for Chapter 11 bankruptcy. The deal includes 23andMe's consumer DNA testing and health research services, but excludes its telehealth arm, Lemonaid Health, which is being shut down.

Proactiveinvestors | 1 month ago
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ratio. The firm just started paying dividends in February, so still lacks dividend growth data long-term.

Seekingalpha | 2 months ago
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition.

Zacks | 2 months ago
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - EVP and CFO Conference Call Participants Tyler Van Buren - TD Cowen Alexandria Hammond - Wolfe Research Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Akash Tewari - Jefferies Carter Gould - Cantor William Pickering - Bernstein Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Operator Welcome to the Regeneron Pharmaceuticals' First Quarter 2025 Earnings Conference Call. My name is Josh, and I will be your operator for today's call.

Seekingalpha | 2 months ago
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 2 months ago
Loading...
Load More